Methods for Affecting Body Composition

• US 20080176804A1
• Filed: 03/25/2008
• Published: 07/24/2008
• Est. Priority Date: 03/04/2004
• Status: Abandoned Application

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Roth, Jonathan David, Mack, Christine Marie
• Application Number:
  US12/055,147
• Publication Number:
  US 20080176804A1
• Time in Patent Office: Days
• US Class Current: 514/12
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents

Abstract

Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.

Claims

1. A method for reducing body fat or body fat gain in a subject while maintaining or increasing lean body mass, the method comprising administering to the subject an amylin agonist, wherein the amylin agonist has at least 80% identity to any of SEQ ID NOs:

1 through 28, wherein the subject is in need of treatment, thereby reducing body fat or body fat gain while maintaining or increasing lean body mass.

2. The method of claim 1 wherein body weight is reduced.

3. The method of claim 1 wherein body weight is maintained or increased.

4. The method of claim 1 wherein the subject is a mammal.

5. The method of claim 4 wherein the mammal is a human.

6. The method of claim 5 wherein the human is overweight or obese.

7. The method of claim 4 wherein the mammal is selected from a group consisting of a chicken, a pig, a cow, a steer, a horse, a sheep, and a goat.

8. The method of claim 1 wherein the amylin agonist has at least 90% identity to any one of SEQ ID NOs:

1 through 28, or an analog or fragment thereof.

9. The method of claim 1 wherein the amylin agonist has at least 95% identity to any one of SEQ ID NOs:

1 through 28.

10. The method of claim 1 wherein the-amylin agonist is administered parenterally.

11. The method of claim 1 wherein the body fat and lean body mass is percent body fat and percent lean body mass, respectively.

20. The method of claim 1 further comprising dieting.

12. A method of altering a body composition of a subject, wherein body fat is reduced and lean body mass is maintained or increased, comprising administering an amylin agonist to the subject, wherein the amylin agonist has at least 80% identity to any one of SEQ ID NOs:

1 through 28, thereby altering the body composition of the subject.

13. The method of claim 12 wherein the subject is overweight or obese.

14. The method of claim 12 wherein the amylin agonist has at least 90% identity to any one of SEQ ID NOs:

1 through 28 or an analog or fragment thereof.

15. The method of claim 12 wherein the amylin agonist has at least 95% identity to any one of SEQ ID NOs:

1 through 28.

16. The method of claim 12 wherein the amylin agonist is administered parenterally.

17. The method of claim 12 wherein body weight is reduced.

18. The method of claim 12 wherein body weight is maintained or increased.

19. The method of claim 12 wherein the body fat and lean body mass is percent body fat and percent lean body mass, respectively.